N/A N=5 Adult Stem Cell Therapy in Liver Insufficiency
Liver Cirrhosis
Primary: Number of Participants With Serious Adverse Events Related to Injection — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Phase 4 N=21 An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers
Hepatic Impairment
Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 49.00; 36.26; 35.94; 69.03 ug/mL
Early Phase 1 N=16 Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
Moderate Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) of Pexidartinib Following a Single Dose in Participants With Moderate Hepatic Impairment Compared to Healthy Participants — 1420…
Phase 1 N=16 Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment
Parkinson's Disease
Primary: Cmax - Maximum Plasma Concentration of BIA 9-1067 — 1108; 559 ng/mL
Phase 1 N=24 Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
Hepatic Impairment
Primary: Assessment of Maximum Observed Plasma Drug Concentration (Cmax) for Telotristat Ethyl and Comparison Between Each HI Group and Healthy Control Group — 4.06; 6.88; 9.99…
Phase 2 N=5 A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency
Liver Disease
Primary: Number of Patients Who Tolerated the Maximum Dose — 5 Participants
Phase 3 N=60 A Human Trial to Evaluate the Efficacy and Safety of Fermented Turmeric in Subjects Showing Mild Hepatic Injury
Mild Hepatic Injury
Primary: Changes in ALT(Alanine Transaminase) — 61.08; 55.68; 44.92; 53.82 IU/L
Phase 4 N=10 The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
Chronic Hepatitis · Chronic Hepatitis C · Chronic Alcoholic Hepatitis
Primary: The Change in Serum Alanine Aminotransferase Level From Baseline to 12 Weeks — 77.5; 105.5 IU/L
N/A N=17 The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.
Cirrhosis · Ascites · Liver Diseases
Primary: Overall Participant Retention Rate Based on Proportion of Participants Who Complete All Study Visits — 10 Participants
N/A N=49 Probiotics for Liver Cirrhosis With Portal Hypertension
Liver Cirrhosis · Portal Hypertension
Primary: Admission Due to Complications Related to Portal Hypertension — 2; 3 participants — p=0.25
Phase 2 N=60 FMT in Cirrhosis and Hepatic Encephalopathy
Cirrhosis · Hepatic Encephalopathy
Primary: Serious Adverse Events Related to FMT — 0; 0; 0; 0 Participants
Phase 1 N=16 Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults
Impaired Liver Function
Primary: Maximum Blood Concentration (Cmax) — 827.5; 587.6; 1589.5; 974.0 ng/L
Phase 1 N=24 Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
Hepatic Impairment · Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) — 532.2; 835.5; 668.3; 658.6 nanogram per milliliter (ng/mL)
Phase 1 N=36 PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
Hepatic Impairment · Liver Diseases · Digestive System Diseases
Primary: AUC — 113.5; 114.6; 423.7; 1042 h*ng/mL
Phase 1 N=33 Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
Hepatic Insufficiency
Primary: AUC (0-inf) of Nintedanib — 200; 674; 92.7; 77.8 ng*h/mL
N/A N=20 Hepatic Mitochondrial Function in Youth
Hepatic Steatosis · Bariatric Surgery Candidate · Adolescent Obesity
Primary: Change in Percentage of Liver Fat Per MRI — -13.93 percentage of liver fat
N/A N=48 Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
Hepatitis C, Chronic · Non-Alcoholic Fatty Liver Disease
Primary: Cholate Shunt Test — 28.0; 37.6; 33.4 SHUNT %
Phase 2 N=47 Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
Acute Liver Failure · Acute Liver Injury
Primary: Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability — 0; 0…
Phase 2 N=18 An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters
Colonoscopy · Bowel Preparation
Primary: Maximum Observed Concentration (Cmax) — 717.0; 499.5; 560.2 µmol/L
Phase 1 N=12 PK Study in Subjects With Severe Hepatic Impairment
Severe Hepatic Impairment · Healthy
Primary: Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax) — 347.6; 280.3 ng/mL
Phase 1 N=24 Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics
Hepatic Insufficiency
Primary: Maximum Observed Plasma Concentration (Cmax) — 30.43; 26.96; 38.85 ng/mL
Phase 1 N=24 Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment
Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) of PF-05221304 — 1220; 1591; 1433; 1592 Nanogram per milliliter (ng/mL)
Phase 1 N=16 Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)
Type 2 Diabetes Mellitus · Hepatic Impairment
Primary: Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin — 1413; 1618 ng•hr/mL
Phase 1 N=24 A Hepatic Impairment Study for PF-04965842.
Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) for PF-04965842 — 1352; 1276; 1426 nanogram per milliliter (ng/mL)
Phase 1 N=16 Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)
Insomnia · Hepatic Insufficiency
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-∞) After Single Dose Suvorexant: Moderate Hepatic Insufficiency Participants…
Phase 1 N=24 An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Primary Biliary Cholangitis · Compensated Cirrhosis · Hepatic Impairment
Primary: Part A: Pharmacokinetic (PK) Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3) — 182.0; 367.7; 359.2; 388.5 nanograms per milliliter (ng/mL)
Phase 1 N=38 A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar
Healthy Volunteer
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Aleglitazar — 98.5; 113; 151 hours (h)*nanogram (ng)/milliliter (mL)
Phase 1 N=28 Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of Total Alectinib — 107; 83.6; 85.5; 85.1 nanograms per milliliter (ng/mL)
Phase 1 N=57 Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment
Hepatic Impairment
Primary: AUC0-tau, Steady State — 96100; 107000; 103000; 69500 h•ng/mL